Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Melphalen flufenamide

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on May 26, 2021 11:33am

66 Views

Post# 33267745

RE:Melphalen flufenamide

On the stock front. Oncopeptides spiked in Mar on approval to a market cap close to 2 billion USD and since have drifter back to 1 billion. I wonder what sort of discussion is going on in Swedish chat boards about valuations?

qwerty22 wrote: We must have mentioned melphalen flufenamide, a PDC that got approval recently.

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple-myeloma

Pretty small trial. Data summarized in table.

https://sparkcures.com/treatment/264/melphalan-flufenamide

There's no question PDCs can work, it's about proving th1902 has activity.